How to deal with resistance to eltrombopag/eltrombopag

Eltrombopag/Eltrombopag (Eltrombopag) is an oral, non-peptide thrombopoietin receptor agonist. It mainly binds to the thrombopoietin receptor to stimulate the proliferation and differentiation of megakaryocytes in the bone marrow, thereby increasing platelet production. This drug is mainly used to treat thrombocytopenia, such as chronic immune thrombocytopenia (ITP), aplastic anemia and other diseases. It is designed to help patients increase platelet counts and reduce or eliminate the risk of bleeding.

Some patients may develop resistance to eltrombopag. This means that with long-term use or increasing doses of the drug, the effects of the drug may gradually diminish or disappear. When this happens, patients and doctors need to take some steps to deal with it. Doctors may recommend that patients undergo genetic testing to determine whether there are genetic variants associated with resistance to eltrombopag. This helps doctors better understand a patient's response to medication and develop a more personalized treatment plan.

Your doctor may consider adjusting your medication dose or switching to another medication. For example, doctors may try to increase the dose of eltrombopag or combine it with other drugs in the hope of achieving better results. If resistance is due to a genetic mutation, doctors may choose another type of drug to replace eltrombopag.

In addition, patients can also try to enhance the body's immunity by improving lifestyle and dietary habits, thereby improving the therapeutic effect of the drug. For example, maintaining adequate sleep, a balanced diet, moderate exercise, etc. can help improve the body's resistance and immunity.